All In Biotech

Drug Trial Radar · NCT06494644

A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.

An Open-label, Single-group, Three-period, Fixed-sequence, Phase I Study to Assess the Pharmacokinetics of AZD6793 Tablets When Administered Alone and in Combination With Itraconazole Capsules in Healthy Adult Female and Male Participants.

Last checked: Nov 19, 2026Latest source record: May 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

Jul 23, 2024

Primary completion

Oct 5, 2024

Study completion Oct 5, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will evaluate the pharmacokinetics (PK) of AZD6793 when administered alone and in combination with itraconazole in healthy adult participants.

Conditions

  • Healthy Participants

Interventions

  • AZD6793Drug

    Participants will receive single dose of AZD6793 on Day 1 in Period 1 and on Day 8 in combination with itraconazole in Period 3.

  • ItraconazoleDrug

    Participants will receive 2 doses of itraconazole on Day 4 and single dose from Day 5 to Day 7 in Period 2. On Day 8 participants will receive single dose of itraconazole combined with AZD6793 and then single dose of itraconazole from Day 9 to Day 10 in Period 3.

  • AZD6793+ ItraconazoleDrug

    Participants will receive a combined dose of AZD6793 and itraconazole on Day 8 in Period 3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma drug concentration (Cmax)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
  2. Area under plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
  3. Area under plasma concentration-time curve from time 0 to infinity (AUCinf)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
  4. Apparent total body clearance (CL/F)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
  5. Terminal elimination half-life (t1/2λz)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
  6. Time to reach maximum observed concentration (tmax)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
  7. Apparent volume of distribution during the terminal phase (Vz/F)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
  8. Ratio Area under plasma concentration-time curve from time 0 to infinity (RAUCinf)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
  9. Ratio Area under plasma concentration-time curve from time 0 to the last quantifiable concentration (RAUClast)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
  10. Ratio Maximum plasma drug concentration (RCmax)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.